Biofrontera Inc.
BFRI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.31 | -0.03 |
| FCF Yield | -170.97% | -581.34% | -83.76% | -20.78% |
| EV / EBITDA | -0.35 | -0.45 | 3.77 | -2.83 |
| Quality | ||||
| ROIC | -162.13% | -157.16% | -63.12% | -64.08% |
| Gross Margin | 50.12% | 48.80% | 47.04% | 47.13% |
| Cash Conversion Ratio | 0.58 | 1.24 | 25.31 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.17% | 12.23% | 15.01% | -2.72% |
| Free Cash Flow Growth | 58.71% | -53.35% | 39.25% | -116.07% |
| Safety | ||||
| Net Debt / EBITDA | 0.07 | -0.22 | -16.98 | 0.67 |
| Interest Coverage | -8.17 | -37.80 | -50.22 | -70.00 |
| Efficiency | ||||
| Inventory Turnover | 2.80 | 1.60 | 2.12 | 2.86 |
| Cash Conversion Cycle | 145.97 | 97.19 | 235.85 | 166.16 |